



MAIL STOP - PCT  
Docket No. 27225U  
Attorneys: GMN/SMH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: FRENKEL, Niza

Appl. No.: 10/567,064

Filing Date: February 3, 2006

Intl. Appl. No.: PCT/IL04/00719

Intl. Filing Date: August 4, 2004

Title: **VACCINATION VECTORS DERIVED FROM LYMPHOTROPIC HUMAN HERPES VIRUSES  
6 AND 7**

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

5. Information Disclosure Statement;
6. PTO Form-1449 citing 23 references; and
7. Copies of 19 of the 23 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,  
**THE NATH LAW GROUP**

March 13, 2007

**THE NATH LAW GROUP**  
112 South West Street  
Alexandria, VA 22314

Gary M. Nath, Reg. No. 26,965  
Susanne M. Hopkins, Reg. No. 33,247  
Customer No. 20529

ct



MAIL STOP - PCT  
Docket No. 27225U  
Attorneys: GMN/SMH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: FRENKEL, Niza

Appl. No.: 10/567,064

Filing Date: February 3, 2006

Intl. Appl. No.: PCT/IL04/00719

Intl. Filing Date: August 4, 2004

Title: **VACCINATION VECTORS DERIVED FROM LYMPHOTROPIC HUMAN HERPES VIRUSES  
6 AND 7**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. ☒ The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☐ The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☐ ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. ☐ The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

- ☐ Certification report(e) below; and  
☐ a check in the amount as required by 1.17(p).

d. ☐ The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed PTO Form-1449.

or

☐ Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


and / or

[XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**THE NATH LAW GROUP**



Gary M. Nath, Reg. No. 26,965  
Susanne M. Hopkins, Reg. No. 33,247  
Customer No. 20529

March 13, 2007

**THE NATH LAW GROUP**  
112 South West Street  
Alexandria, VA 22314

ct



<b>PTO FORM-1449</b>  <b>INFORMATION</b> <b>DISCLOSURE</b> <b>CITATION</b>		Inventor: FRENKEL, Niza			
		Appl. No.: 10/567,064		Intl. Appl. No: PCT/IL04/00719	
		Filing Date: February 3, 2006		Intl. Filing Date: August 4, 2004	
<b>U.S. PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
	A1	6,503,752	07 Jan 2003	Frenkel	09 Nov 1994
	A2	5,194,601	16 Mar 1993	Sugden et al.	18 Sep 1989
	A3	6,544,780	08 Apr 2003	Wang	02 Jun 2000
	A4	5,230,997	27 Jul 1993	Frenkel	19 Jul 1990
	A5				
	A6				
	A7				
<b>FOREIGN PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Public. Date	Country	Translation
	A8	WO 02/056828	25 Jul 2002	WO	N/A
	A9	WO 99/07869	08 Feb 1999	WO	N/A
	A10				
	A11				
<b>OTHER</b>					
Exam. Initial					
	A12	Ablashi et al., "Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates." <u>Virology</u> , v.184:545-552, 1991.			
	A13	Borenstein et al., "Use of an amplicon-6 vector derived from Human Herpesvirus 6 for efficient expression of membrane-associated and secreted proteins in T cells." <u>J. Virol.</u> , v.78:4730-4743, 2004.			
	A14	Engels et al., "Retroviral vectors for high-level transgene expression in T lymphocytes." <u>Hum. Gene Ther.</u> , v.14:1155-1168, 2003.			
	A15	Frenkel and Hoffman, <u>Virology</u> . 3 <sup>rd</sup> Edition: Lippincott, Raven Press, pp.2609-2633 (1996).			
	A16	Frenkel et al., "Isolation of a new herpesvirus from human CD4+ T cells." <u>Proc. Natl. Acad. Sci. USA</u> , v.87:748-752, 1990.			
	A17	Frenkel et al., "Bone marrow transplant recipients harbor the B variant of human herpesvirus 6." <u>Bone Marrow Transplant</u> , v.14:839-843, 1994.			
	A18	Frenkel et al., "The herpes simplex virus amplicon - a versatile defective virus vector." <u>Gene Therapy</u> , v.1:540-546, 1994			
	A19	Hanke et al., "Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine." <u>J. Gen. Virol.</u> , v.84:361-368, 2003.			
	A20	Meeker et al., "Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies including anaplastic large cell lymphoma and Hodgkin's disease." <u>Clin. Cancer Res.</u> , v.3:357-364, 1997.			
	A21	Katsafanas et al., "In vitro activation of human herpesviruses 6 and 7 from latency." <u>Proc. Natl. Acad. Sci. USA</u> , v.93:9788-9792, 1996.			

<b>PTO FORM-1449</b>		Inventor: FRENKEL, Niza	
<b><u>INFORMATION</u></b> <b><u>DISCLOSURE</u></b> <b><u>CITATION</u></b>		Appl. No.: 10/567,064	Intl. Appl. No: PCT/IL04/00719
		Filing Date: February 3, 2006	Intl. Filing Date: August 4, 2004
<b>OTHER (CONT.)</b>			
Exam. Initial			
	A22	Taylor-Papadimitriou et al., "MUC1 and cancer." <u>Biochem. Biophys. Acta.</u> , 1455(2-3):301-313, 1999.	
	A23	D. Pellet, "Human herpesviruses 6A, 6B, and 7 and their replication." <u>Virology</u> , v.2(80):2769-2784, 2002.	
	A24	Rapaport et al., "Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients." <u>Transpl. Infec. Dis.</u> , v.4:10-16, 2002.	
	A25	Romi et al., "Tamplicon-7, a novel T-lymphotropic vector derived from human herpesvirus 7." <u>J. Virol.</u> , v.73:7001-7007, 1999.	
	A26	Schirmer et al., "Differentiation between two distinct classes of viruses now classified as human herpes virus 6." <u>Proc. Natl. Acad. Sci. USA</u> , v.88:199-208, 1991.	
	A27	Wyatt and Frenkel, "Human herpes virus 7 is a constitutive inhabitant of adult human saliva." <u>J. Virol.</u> , v.66:3206-3209, 1992.	
	A28	K. Yamanishi, "Human herpesvirus 6." <u>Microbiol. Immunol.</u> , v.36:551-561, 1992.	
Examiner		Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			